Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine

Brian Hitsman, Bonnie Spring, Belinda Borrelli, Raymond Niaura, George D. Papandonatos

Research output: Contribution to journalArticle

Abstract

The authors examined whether serum fluoxetine levels influence behavioral treatment adherence and smoking cessation outcome. Nondepressed smokers (N = 989) from 16 centers were randomized on a double-blind basis to receive either fluoxetine (30 or 60 mg) or placebo plus 9 sessions of behavioral smoking cessation treatment. Fluoxetine and norfluoxetine blood levels were assayed 1 week after the quit date. Logistic regression was used to predict treatment completion and cessation outcome, controlling for gender, age, treatment site, and degree of nicotine dependence. Higher steady-state fluoxetine blood levels (fluoxetine + norfluoxetine) predicted less likelihood of dropping out, χ2(1, N = 820) = 3.9, p < .05, and more likelihood of being abstinent, χ2(1, N = 513) = 18.1, p < .001. Attaining a higher fluoxetine blood level improved the likelihood of completing behavioral treatment and increased the probability of achieving abstinence.

Original languageEnglish (US)
Pages (from-to)355-362
Number of pages8
JournalExperimental and Clinical Psychopharmacology
Volume9
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Fluoxetine
Smoking Cessation
Antidepressive Agents
Drug Therapy
Withholding Treatment
Therapeutics
Tobacco Use Disorder
Logistic Models
Placebos
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine. / Hitsman, Brian; Spring, Bonnie; Borrelli, Belinda; Niaura, Raymond; Papandonatos, George D.

In: Experimental and Clinical Psychopharmacology, Vol. 9, No. 4, 2001, p. 355-362.

Research output: Contribution to journalArticle

@article{be494cf22f344f2fb5a3aacf09315fd3,
title = "Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine",
abstract = "The authors examined whether serum fluoxetine levels influence behavioral treatment adherence and smoking cessation outcome. Nondepressed smokers (N = 989) from 16 centers were randomized on a double-blind basis to receive either fluoxetine (30 or 60 mg) or placebo plus 9 sessions of behavioral smoking cessation treatment. Fluoxetine and norfluoxetine blood levels were assayed 1 week after the quit date. Logistic regression was used to predict treatment completion and cessation outcome, controlling for gender, age, treatment site, and degree of nicotine dependence. Higher steady-state fluoxetine blood levels (fluoxetine + norfluoxetine) predicted less likelihood of dropping out, χ2(1, N = 820) = 3.9, p < .05, and more likelihood of being abstinent, χ2(1, N = 513) = 18.1, p < .001. Attaining a higher fluoxetine blood level improved the likelihood of completing behavioral treatment and increased the probability of achieving abstinence.",
author = "Brian Hitsman and Bonnie Spring and Belinda Borrelli and Raymond Niaura and Papandonatos, {George D.}",
year = "2001",
doi = "10.1037/1064-1297.9.4.355",
language = "English (US)",
volume = "9",
pages = "355--362",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine

AU - Hitsman, Brian

AU - Spring, Bonnie

AU - Borrelli, Belinda

AU - Niaura, Raymond

AU - Papandonatos, George D.

PY - 2001

Y1 - 2001

N2 - The authors examined whether serum fluoxetine levels influence behavioral treatment adherence and smoking cessation outcome. Nondepressed smokers (N = 989) from 16 centers were randomized on a double-blind basis to receive either fluoxetine (30 or 60 mg) or placebo plus 9 sessions of behavioral smoking cessation treatment. Fluoxetine and norfluoxetine blood levels were assayed 1 week after the quit date. Logistic regression was used to predict treatment completion and cessation outcome, controlling for gender, age, treatment site, and degree of nicotine dependence. Higher steady-state fluoxetine blood levels (fluoxetine + norfluoxetine) predicted less likelihood of dropping out, χ2(1, N = 820) = 3.9, p < .05, and more likelihood of being abstinent, χ2(1, N = 513) = 18.1, p < .001. Attaining a higher fluoxetine blood level improved the likelihood of completing behavioral treatment and increased the probability of achieving abstinence.

AB - The authors examined whether serum fluoxetine levels influence behavioral treatment adherence and smoking cessation outcome. Nondepressed smokers (N = 989) from 16 centers were randomized on a double-blind basis to receive either fluoxetine (30 or 60 mg) or placebo plus 9 sessions of behavioral smoking cessation treatment. Fluoxetine and norfluoxetine blood levels were assayed 1 week after the quit date. Logistic regression was used to predict treatment completion and cessation outcome, controlling for gender, age, treatment site, and degree of nicotine dependence. Higher steady-state fluoxetine blood levels (fluoxetine + norfluoxetine) predicted less likelihood of dropping out, χ2(1, N = 820) = 3.9, p < .05, and more likelihood of being abstinent, χ2(1, N = 513) = 18.1, p < .001. Attaining a higher fluoxetine blood level improved the likelihood of completing behavioral treatment and increased the probability of achieving abstinence.

UR - http://www.scopus.com/inward/record.url?scp=0035210281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035210281&partnerID=8YFLogxK

U2 - 10.1037/1064-1297.9.4.355

DO - 10.1037/1064-1297.9.4.355

M3 - Article

VL - 9

SP - 355

EP - 362

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 4

ER -